Novo Nordisk A/S (NYSE:NVO) Shares Bought by Savvy Advisors Inc.

Savvy Advisors Inc. grew its stake in Novo Nordisk A/S (NYSE:NVO) by 91.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,123 shares of the company’s stock after acquiring an additional 3,395 shares during the quarter. Savvy Advisors Inc.’s holdings in Novo Nordisk A/S were worth $613,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of NVO. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares during the period. Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC increased its holdings in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after buying an additional 243 shares during the last quarter. Hager Investment Management Services LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $46,000. Finally, Halbert Hargrove Global Advisors LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $47,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 5.8 %

NVO opened at $64.76 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $290.59 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 0.90 and a beta of 0.61. The business has a fifty day moving average price of $77.87 and a 200 day moving average price of $93.34. Novo Nordisk A/S has a 12 month low of $59.32 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S’s payout ratio is 49.54%.

Analysts Set New Price Targets

Several research firms have issued reports on NVO. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 7th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.